Formulary Chapter 13: Skin - Full Chapter
|
13.02.01 |
Emollients - preparations containing urea |
|
|
Dermatonics Once Heel Balm®
(Urea 25%)
|
Restricted
|
JFC approved for primary and secondary care for treatment of anhidrotic, fissured, calloused and hard foot skin in diabetic patients at high risk of ulceration (March 2018) Provider notes - NMUH:
- RFL:
- RNOH:
- UCLH:
- WH:
- See indication above.
- Restricted to podiatry use ONLY
|
13.02.01 |
Emollients - with antimicrobials |
|
|
13.02.01.01 |
Emollient bath and shower preparations |
|
|
E45® Itch Relief Cream
(Urea 5%)

|
Non Formulary
|
|
Flexitol® heel balm
(Urea 25%)

|
Non Formulary
|
|
Hydromol® Intensive cream
(Urea 10%)
(Preparation containing Urea)

|
Non Formulary
|
|
Key |
Traffic Light Status Information
Status |
Description |
 
|
Medicines that should be initiated by a specialist. Prescribing can be transferred to primary care once the patient has been stabilised.
Shared care: For drugs with regular, ongoing need for monitoring and/or assessment of efficacy or toxicity. Prior agreement must be obtained by the specialist from the primary care provider before prescribing responsibility is transferred. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s) (DTC) and approved by the North Central London JFC.
Fact sheet: For drugs with some concerns surrounding safety or efficacy but do not require regular monitoring and/or monitoring of effectiveness/toxicity. |
 
|
Medicines which should normally be prescribed by specialists only (hospital only).
For patients already receiving prescriptions in primary care - continue. No new patients to receive prescriptions in primary care.
See link for the complete NCL Red List https://www.ncl-mon.nhs.uk/wp-content/uploads/2017/08/ncl_red_list.pdf |
 
|
Medicines not recommended for routine use in primary or secondary care.
Medicines, which the North Central London JFC has actively reviewed and does not recommend for use at present due to limited clinical and/or cost effective data. |
|
|